Bak Antibody - #AF0119

>>买2送1 进行中>>
>>赠JD卡 进行中>>
(4)   (9)  
产品: Bak 抗体
货号: AF0119
描述: Rabbit polyclonal antibody to Bak
应用: WB IHC IF/ICC
文献验证: WB
反应: Human, Mouse, Rat
预测: Bovine, Horse, Dog
蛋白号: Q16611
RRID: AB_2833303

浏览相似产品>>

   规格 价格 库存
 50ul RMB¥ 1250 现货
 100ul RMB¥ 2300 现货
 200ul RMB¥ 3000 现货

货期: 当天发货

联系销售
相关下载
MS Report
HPLC Report
MSDS
说明书
COA
实验方案
WB Handbook
IHC Protocol
IF/ICC Protocol

产品描述

来源:
Rabbit
应用:
WB 1:500-1:3000, IHC 1:50-1:200, IF/ICC 1:100-1:500
*The optimal dilutions should be determined by the end user.
*Tips:

WB: 适用于变性蛋白样本的免疫印迹检测. IHC: 适用于组织样本的石蜡(IHC-p)或冰冻(IHC-f)切片样本的免疫组化/荧光检测. IF/ICC: 适用于细胞样本的荧光检测. ELISA(peptide): 适用于抗原肽的ELISA检测.

反应:
Human, Mouse, Rat
克隆:
Polyclonal
特异性:
Bak Antibody detects endogenous levels of total Bak.
RRID:
AB_2833303
引用格式: Affinity Biosciences Cat# AF0119, RRID:AB_2833303.
偶联:
Unconjugated.
纯化:
The antiserum was purified by peptide affinity chromatography using SulfoLink™ Coupling Resin (Thermo Fisher Scientific).
保存:
Rabbit IgG in phosphate buffered saline , pH 7.4, 150mM NaCl, 0.02% sodium azide and 50% glycerol. Store at -20 °C. Stable for 12 months from date of receipt.
别名:

展开/折叠

Apoptosis regulator BAK; BAK; BAK like; Bak NT; BAK_HUMAN; Bak1; Bcl 2 homologous antagonist/killer; Bcl 2 like 7 protein; Bcl-2 homologous antagonist/killer; Bcl-2-like protein 7; BCL2 antagonist/killer 1; Bcl2 like 7 Protein; Bcl2-L-7; BCL2L7; CDN1; Cell death inhibitor 1; MGC117255; MGC3887; NBak; Pro apoptotic protein BAK;

抗原和靶标

免疫原:

A synthesized peptide derived from human Bak, corresponding to a region within N-terminal amino acids.

基因/基因ID:
BAK1(578)
描述:
Bak1 In the presence of an appropriate stimulus, accelerates programmed cell death by binding to, and antagonizing the anti- apoptotic action of BCL2 or its adenovirus homolog E1B 19k protein. Low micromolar levels of zinc ions inhibit the promotion of apoptosis. Belongs to the Bcl-2 family. Interacts with BCL2A1. Homodimer. Formation of the homodimer is zinc-dependent. Forms heterodimers with BCL2, E1B 19k protein, and BCL2L1 isoform Bcl-X(L). Interacts with myxoma virus protein M11L

研究领域

· Cellular Processes > Cell growth and death > Apoptosis.   (View pathway)

· Cellular Processes > Cell growth and death > Apoptosis - multiple species.   (View pathway)

· Genetic Information Processing > Folding, sorting and degradation > Protein processing in endoplasmic reticulum.   (View pathway)

· Human Diseases > Drug resistance: Antineoplastic > Platinum drug resistance.

· Human Diseases > Infectious diseases: Viral > Human papillomavirus infection.

· Human Diseases > Cancers: Overview > Pathways in cancer.   (View pathway)

· Human Diseases > Cancers: Overview > Transcriptional misregulation in cancer.

· Human Diseases > Cancers: Overview > Viral carcinogenesis.

· Human Diseases > Cancers: Overview > MicroRNAs in cancer.

· Human Diseases > Cancers: Specific types > Colorectal cancer.   (View pathway)

· Human Diseases > Cancers: Specific types > Pancreatic cancer.   (View pathway)

· Human Diseases > Cancers: Specific types > Endometrial cancer.   (View pathway)

· Human Diseases > Cancers: Specific types > Glioma.   (View pathway)

· Human Diseases > Cancers: Specific types > Thyroid cancer.   (View pathway)

· Human Diseases > Cancers: Specific types > Basal cell carcinoma.   (View pathway)

· Human Diseases > Cancers: Specific types > Melanoma.   (View pathway)

· Human Diseases > Cancers: Specific types > Chronic myeloid leukemia.   (View pathway)

· Human Diseases > Cancers: Specific types > Small cell lung cancer.   (View pathway)

· Human Diseases > Cancers: Specific types > Non-small cell lung cancer.   (View pathway)

· Human Diseases > Cancers: Specific types > Breast cancer.   (View pathway)

· Human Diseases > Cancers: Specific types > Hepatocellular carcinoma.   (View pathway)

· Human Diseases > Cancers: Specific types > Gastric cancer.   (View pathway)

文献引用

1). Injectable Hydrogel-Encapsulating Pickering Emulsion for Overcoming Lenvatinib-Resistant Hepatocellular Carcinoma via Cuproptosis Induction and Stemness Inhibition. Polymers, 2024 (PubMed: 39274051) [IF=5.0]
2). Bisimidazolium Salt Glycosyltransferase Inhibitors Suppress Hepatocellular Carcinoma Progression In Vitro and In Vivo. Pharmaceuticals, 2022 (PubMed: 35745636) [IF=4.6]

Application: WB    Species: Human    Sample: HepG2 cells

Figure 7 Treatment with C20/C22 induced ER stress and mitochondrial dysfunction increased the expression of proapoptotic proteins. HepG2 cells were treated with 2 and 3 μM of C20/C22 for 24 h. (A,B) WB analysis of the protein expression in HepG2 cells treated with 2 μM of C20/C22 for 0, 6, 12, and 24 h. The presented values correspond to the mean ± SD for three independent experiments. The p-value was analyzed by one-way ANOVA followed by Tukey’s test using GraphPad Prism version 8.00. *** p < 0.001, and **** p < 0.0001 vs. 0 h/control group. (C) JC-1 staining was performed to measure the MMP (n = 3), CCCP, and carbonyl cyanide 3-chlorophenylhydrazone. (D) C20/C22-treated cells were stained with DCFH-DA, and the relative levels of intracellular ROS were determined via fluorescence microscopy (n = 3). Scale bars, 50 µm.
3). lncRNA RP11-10A14. 5: a potential prognosis biomarker for LUAD through regulation on proliferation and metastasis. Discover-Oncology, 2022 (PubMed: 35575835) [IF=2.2]

Application: WB    Species: Human    Sample: H1299-RP11OV and H1299-∆RP11 cells

Fig. 5Effect of RP11-10A14.5 on the tumor metastasis markers and cell apoptosis. Relative expression of E-cadherin (A), Vimentin (B) and N-Cadherin (C) mRNA in H1299-RP11OV and H1299-∆RP11 cells. Expression of E-Cadherin (D), Vimentin (E) and N-Cadherin (F) in H1299-RP11OV and H1299-∆RP11 cells verified by IF. F Cell apoptosis rate of H1299-RP11OV and H1299-∆RP11 cells. G Relative expression of Caspase-3, Bax and Bak mRNA in H1299-RP11OV and H1299-∆RP11 cells. H Protein expression of Pro-Caspase-3, Cleaved-Caspase-3, Bak and Bax in H1299-RP11OV and H1299-∆RP11 cells.
4). Association of CUL4B with the pathogenesis of age-related cataract. International ophthalmology, 2024 (PubMed: 38937308) [IF=1.4]

限制条款

产品的规格、报价、验证数据请以官网为准，官网链接：www.affbiotech.com | www.affbiotech.cn（简体中文）| www.affbiotech.jp（日本語）

产品的数据信息为Affinity所有，未经授权不得收集Affinity官网数据或资料用于商业用途，对抄袭产品数据的行为我们将保留诉诸法律的权利。

产品相关数据会因产品批次、产品检测情况随时调整，如您已订购该产品，请以订购时随货说明书为准，否则请以官网内容为准，官网内容有改动时恕不另行通知。

Affinity保证所销售产品均经过严格质量检测。如您购买的商品在规定时间内出现问题需要售后时，请您在Affinity官方渠道提交售后申请。

产品仅供科学研究使用。不用于诊断和治疗。 

产品未经授权不得转售。

Affinity Biosciences将不会对在使用我们的产品时可能发生的专利侵权或其他侵权行为负责。Affinity Biosciences, Affinity Biosciences标志和所有其他商标所有权归Affinity Biosciences LTD.